^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mipasetamab uzoptirine (ADCT-601)

    i
    Other names: ADCT-601, ADCT 601, BGB601, ADCT601, BGB-601, BGB 601
    Company:
    Overland ADCT BioPharma
    Drug class:
    DNA replication inhibitor, AXL-targeted antibody-drug conjugate
    Related drugs:
    4ms
    Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets. (PubMed, bioRxiv)
    We identified several receptor tyrosine kinases (RTKs) enriched in MES-dominant samples and showed that AXL targeting with ADCT-601 was potently cytotoxic in MES-dominant cell lines and showed specific anti-tumor activity in a MES cell line-derived xenograft...Several plasma membrane proteins are being developed as immunotherapeutic targets in this disease. Here we define which cell surface proteins are susceptible to epigenetically regulated downregulation during an adrenergic to mesenchymal cell state switch and propose immunotherapeutic strategies to anticipate and circumvent acquired immunotherapeutic resistance.
    Journal • IO biomarker • Tumor cell
    |
    AXL (AXL Receptor Tyrosine Kinase) • CD276 (CD276 Molecule) • L1CAM (L1 cell adhesion molecule)
    |
    mipasetamab uzoptirine (ADCT-601)
    7ms
    ADCT-601-102: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, ADC Therapeutics S.A. | N=196 --> 260
    Enrollment change • Combination therapy • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    11ms
    ADCT-601-102: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=196, Recruiting, ADC Therapeutics S.A. | Phase classification: P1b --> P1
    Phase classification
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    1year
    ADCT-601-102: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1b, N=196, Recruiting, ADC Therapeutics S.A. | N=66 --> 196
    Enrollment change • Combination therapy • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    1year
    PRE-CLINICAL ACTIVITY OF ADCT-601, AN ANTIBODY-DRUG CONJUGATE TARGETING AXL IN SOFT-TISSUE SARCOMA (CTOS 2023)
    No abstract available
    Preclinical
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    mipasetamab uzoptirine (ADCT-601)
    2years
    Ultrasound-induced cavitation enhances therapeutic efficacy of AXL-targeting ADC leading to improved survival in a human xenograft model of renal cancer. (AACR-NCI-EORTC 2022)
    The purpose of this study was to test a suboptimal single dose of mipasetamab uzoptirine (ADCT-601), an ADC targeting the AXL protein, in combination with ultrasound-induced cavitation in a preclinical mouse model of renal cancer...This was demonstrated for a suboptimal ADC dose, indicating that ultrasound-mediated drug delivery could be used to reduce the administered dose while preserving therapeutic efficacy. These preclinical data warrant further evaluation of this promising combination in the clinic.
    Preclinical
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    mipasetamab uzoptirine (ADCT-601)
    over2years
    ADCT-601-102: A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1b, N=66, Recruiting, ADC Therapeutics S.A. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    over2years
    A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1b, N=66, Not yet recruiting, ADC Therapeutics S.A.
    New P1 trial • Combination therapy
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    over2years
    Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. (PubMed, Mol Cancer Ther)
    Notably, ADCT-601 had antitumor activity in a monomethyl auristatin E-resistant lung-cancer model and synergized with the PARP inhibitor olaparib in a BRCA1-mutated ovarian cancer model. ADCT-601 was well tolerated at doses of up to 6 mg/kg and showed excellent stability in vivo. These preclinical results warrant further evaluation of ADCT-601 in the clinic.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • AXL (AXL Receptor Tyrosine Kinase)
    |
    BRCA1 mutation • AXL expression
    |
    Lynparza (olaparib) • mipasetamab uzoptirine (ADCT-601)
    over2years
    AXL as a therapeutic target in adenoid cystic carcinoma: preclinical evaluation of AXL targeting antibody-drug conjugate (ADCT-601) (AACR 2022)
    This study demonstrated that ADCT-601 induced a potent and specific in vitro and in-vivo anti-tumor activities in AXL expressing ACC models and suggests further development of ADCT-601 in biomarker driven clinical trials.
    Preclinical • Late-breaking abstract
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    AXL expression • AXL-L
    |
    mipasetamab uzoptirine (ADCT-601)
    almost5years
    Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=75, Suspended, ADC Therapeutics S.A. | Recruiting --> Suspended
    Clinical • Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative • ER negative
    |
    mipasetamab uzoptirine (ADCT-601)